Epileptogenesis and Tumorigenesis in Glioblastoma: Which Relationship?
glioblastoma
marker
prognosis
seizures
survival
tumor-related epilepsy
Journal
Medicina (Kaunas, Lithuania)
ISSN: 1648-9144
Titre abrégé: Medicina (Kaunas)
Pays: Switzerland
ID NLM: 9425208
Informations de publication
Date de publication:
26 Sep 2022
26 Sep 2022
Historique:
received:
04
08
2022
revised:
17
09
2022
accepted:
21
09
2022
entrez:
27
10
2022
pubmed:
28
10
2022
medline:
29
10
2022
Statut:
epublish
Résumé
Epilepsy is reported in 29-52% of patients with glioblastoma (GBM) and has an important role in the natural history of this tumor and patients' life quality. Although GBM is less epileptogenic than lower-grade gliomas, seizures are usually more difficult to control with common antiseizure medications; drug resistance is found in 20% of cases. Recent studies suggest that seizures at the onset of GBM could be a possible favorable independent prognostic factor in patients. Moreover, a growing body of evidence shows that many molecular mechanisms that influence epileptogenesis often regulate GBM growth and invasiveness, sometimes favoring or counteracting the tumor, respectively. The better-characterized players include glutamate, γ-aminobutyric acid, aquaporin-4, and hypoxia-activated molecules. However, currently available data on the molecular basis of epileptogenesis, tumorigenesis, and their relationship is incomplete or discordant and further research is urgently needed on this topic.
Identifiants
pubmed: 36295510
pii: medicina58101349
doi: 10.3390/medicina58101349
pmc: PMC9606940
pii:
doi:
Substances chimiques
Glutamates
0
gamma-Aminobutyric Acid
56-12-2
Aquaporins
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
Epilepsy Behav. 2018 Jan;78:30-36
pubmed: 29172136
Am J Pathol. 2012 May;180(5):2108-19
pubmed: 22440258
Curr Oncol. 2022 Feb 04;29(2):881-891
pubmed: 35200574
BMC Neurol. 2020 Oct 21;20(1):382
pubmed: 33087049
Int J Radiat Oncol Biol Phys. 1992;24(1):55-7
pubmed: 1512163
Cancers (Basel). 2019 Jan 04;11(1):
pubmed: 30621209
Neurology. 2012 Aug 28;79(9):883-9
pubmed: 22843268
Neuro Oncol. 2013 May;15(5):618-25
pubmed: 23410662
Neurooncol Pract. 2021 May 28;8(5):501-517
pubmed: 34589231
Epilepsia. 2013 Dec;54 Suppl 9:30-4
pubmed: 24328869
PLoS One. 2020 Mar 11;15(3):e0229274
pubmed: 32160197
Oncogene. 2017 Feb 9;36(6):777-786
pubmed: 27375015
J Neurosurg. 2017 Jun;126(6):1772-1778
pubmed: 27341048
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Clin Neurol Neurosurg. 2016 Dec;151:113-119
pubmed: 27821299
Front Mol Neurosci. 2022 Jun 27;15:903115
pubmed: 35832394
Mol Med. 2012 Sep 25;18:1147-51
pubmed: 22714714
Oncotarget. 2017 May 9;8(19):32345-32355
pubmed: 28423683
Clin Neurol Neurosurg. 2018 Jan;164:75-80
pubmed: 29202377
J Neurooncol. 2009 Jul;93(3):319-24
pubmed: 19183851
J Neurooncol. 2018 May;138(1):49-53
pubmed: 29404978
J Clin Invest. 2020 May 1;130(5):2286-2300
pubmed: 32250339
JAMA. 2013 Nov 6;310(17):1842-50
pubmed: 24193082
Int J Mol Sci. 2020 Nov 11;21(22):
pubmed: 33187183
World Neurosurg. 2018 Mar;111:e539-e545
pubmed: 29288860
Neuro Oncol. 2016 May;18(5):700-6
pubmed: 26420896